Profile data is unavailable for this security.
About the company
Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.
- Revenue in SEK (TTM)5.87m
- Net income in SEK-41.41m
- Incorporated2006
- Employees5.00
- LocationEnorama Pharma ABVastra Varvsgatan 19MALMO 211 77SwedenSWE
- Phone+46 40140620
- Websitehttps://www.enorama.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncozenge AB | 0.00 | -11.78m | 47.32m | -- | -- | 3.33 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 2.36m | -13.86m | 49.02m | 8.00 | -- | 1.41 | -- | 20.77 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Ziccum AB | 4.15m | -25.18m | 50.86m | 10.00 | -- | 7.00 | -- | 12.27 | -1.57 | -1.57 | 0.2578 | 0.1423 | 0.2623 | -- | 4.14 | 518,250.00 | -159.33 | -68.51 | -267.20 | -76.47 | -- | -- | -607.43 | -2,598.03 | -- | -- | 0.1454 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| Arctic Bioscience AS | 31.38m | -48.32m | 52.72m | 20.00 | -- | 0.2245 | -- | 1.68 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Odi Pharma AB (publ) | 22.45m | 355.97k | 54.41m | -- | 141.09 | 22.65 | 151.60 | 2.42 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Elicera Therapeutics AB | 12.07m | -20.79m | 61.76m | 2.00 | -- | 2.39 | -- | 5.12 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| StenoCare A/S | 3.10m | -25.48m | 68.45m | 9.00 | -- | 2.31 | -- | 22.06 | -0.888 | -0.888 | 0.108 | 0.9428 | 0.0657 | -- | 1.81 | -- | -53.98 | -28.16 | -70.78 | -35.47 | -- | -- | -821.10 | -371.06 | 1.14 | -7.59 | 0.1659 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 97.20m | -- | -- | 5.78 | -- | 1,117.26 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Pila Pharma AB | 1.03m | -6.92m | 120.17m | 0.00 | -- | 40.93 | -- | 116.22 | -0.3165 | -0.3165 | 0.049 | 0.1082 | 0.2602 | -- | 8.21 | 1,034,020.00 | -174.06 | -108.88 | -276.40 | -121.45 | -406.94 | -42.67 | -668.94 | -1,577.64 | -- | -163.35 | 0.00 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Corline Biomedical AB | 14.01m | -9.63m | 141.84m | 14.00 | -- | 1.68 | -- | 10.13 | -0.4482 | -0.4482 | 0.6518 | 3.93 | 0.1456 | -- | 6.12 | 1,077,462.00 | -10.01 | -5.71 | -10.80 | -6.24 | 137.11 | 128.60 | -68.77 | -38.46 | -- | -740.00 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Vivesto AB | 0.00 | -98.92m | 150.38m | 4.00 | -- | 0.8398 | -- | -- | -0.1839 | -0.1839 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -39.70 | -- | -43.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Enorama Pharma AB | 5.87m | -41.41m | 233.43m | 5.00 | -- | 6.02 | -- | 39.77 | -0.9211 | -0.9211 | 0.1295 | 0.6408 | 0.1413 | 1.20 | 2.94 | 1,173,800.00 | -99.66 | -73.56 | -147.35 | -104.85 | -32.71 | 43.36 | -705.54 | -557.42 | 2.00 | -29.36 | 0.0094 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| Orexo AB | 595.80m | -105.30m | 326.28m | 113.00 | -- | -- | -- | 0.5476 | -3.05 | -3.05 | 17.28 | -0.7896 | 0.7609 | 1.17 | 2.32 | 5,136,207.00 | -13.45 | -6.41 | -20.81 | -9.99 | 88.28 | 86.76 | -17.67 | -11.83 | 1.47 | -0.7557 | 1.05 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
Data as of Nov 22 2024. Currency figures normalised to Enorama Pharma AB's reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Oct 2024 | 12.46k | 0.02% |
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
